Therapy News and Research

RSS

UH researchers to discuss computational surgery at MITIE

More than a dozen University of Houston (UH) researchers will be making presentations, ranging from robot-assisted surgery techniques to improving heart and breast surgery procedures, at the third annual international conference in computational surgery Jan. 26-28. The symposium will be held at The Methodist Hospital Research Institute (TMHRI) in Houston.

25 Jan 2011

ASCO urges physicians, medical schools to improve quality of life for people with cancer

The American Society of Clinical Oncology today called on physicians, medical schools, insurers, and others to help improve quality of life for people with advanced cancer.

25 Jan 2011

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

Diamyd completed screening for US Phase III study in type 1 diabetes. The screening of patients for the US Phase III study, DiaPrevent, was completed, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age had, at the completion of screening, been enrolled in the study and received their first injection of the antigen-based therapy Diamyd® or placebo.

25 Jan 2011

UB's therapeutic program helps teens with ADHD to become better drivers

A University at Buffalo researcher's work with a state-of-the-art driving simulator is making better drivers among those considered to be the most risky motorists on the road: teens with ADHD.

25 Jan 2011

Octapharma supports development of 'Diagnosis and Management of von Willebrand Disease' CE supplement

An unrestricted grant from Octapharma USA supported the development of a Continuing Education (CE) initiative entitled the "The Diagnosis and Management of von Willebrand Disease," a program of the National Home Infusion Association (NHIA).

25 Jan 2011

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.

25 Jan 2011

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.

25 Jan 2011

Male celebrities admit to undergoing hair restoration surgery

An interesting statistic: more than half of hair loss sufferers would be more inclined to consider having a hair transplant if celebrities or public figures were more open about hair restoration surgery, and men are more likely to be influenced than women.

25 Jan 2011

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

The medical device company cerbomed cooperated with the Clinic for Psychiatry and Psychotherapy of the University of Regensburg 2010 on a randomized, controlled study into somatosensory pain processing. The study, lead by Prof. Dr. Peter Eichhammer and Dr. Volker Busch, aimed to judge the pain-relieving effect of transcutaneous Vagus Nerve Stimulation (t-VNS).

25 Jan 2011

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Glioblastoma, the most common and lethal form of brain cancer and the disease that killed Massachusetts Senator Ted Kennedy, resists nearly all treatment efforts, even when attacked simultaneously on several fronts. One explanation can be found in the tumor cells' unexpected flexibility, discovered researchers at the Salk Institute for Biological Studies.

25 Jan 2011

World's largest sterile compounding center for oncology patients

Health Robotics today announced the official opening and live operation of the largest Sterile Compounding Center for Oncology patients in the world. Akdeniz University Hospital in Antalya (Turkey) compounds 90% of its 80.000 annual chemotherapy intravenous doses with 4 CytoCare robots and related Health Robotics' technology, or an average of 325 patient doses per 6-hour work cycle.

25 Jan 2011

Diamyd Medical to report European Phase III trial results for type 1 diabetes

Diamyd Medical's President and CEO Elisabeth Lindner states in the CEO comments in today's quarterly report that the Company expects to begin reporting the results from the European Phase III trial in type 1 diabetes as planned in late spring 2011.

25 Jan 2011

Patients with chronic depression can benefit from pioneering neurosurgical treatment

Pioneering neurosurgical treatment, a world first in Bristol, which very accurately targets brain networks involved in depression, could help people who suffer with severe and intractable depression.

25 Jan 2011

Breast and lung cancer: Shared risk and treatment

New research has shown that women who are heavy smokers before menopause, especially prior to giving birth, may significantly increase their risk of developing breast cancer. In the US study looking at almost 150,000 women from the Nurses’ Health Study; it was found that breast cancer rates increased with higher levels of smoking among younger age groups. The study appeared in the journal Archives of Internal Medicine.

24 Jan 2011

Blocking rogue gene may stop cancer spread: Study

In a new breakthrough British scientists have discovered a “rogue gene” which helps cancer spread around the body and add that this could mean specific therapy, if developed against the gene, could stop cancer spread.

24 Jan 2011

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.

24 Jan 2011

St. Jude Medical's Athena programmer DBS system receives Australian TGA approval

St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Australian Therapeutic Goods Administration (TGA) of its Athena™ programmer, a deep brain stimulation (DBS) therapy management system.

24 Jan 2011

FDA accepts Optimer's fidaxomicin NDA for filing

Optimer Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI.

24 Jan 2011

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

The Methodist DeBakey Heart & Vascular Center was chosen today as a site for a critical percutaneous heart valve study. As part of the research study, Methodist physicians will replace diseased cardiac valves through a single, tiny puncture hole in the research subject's groin.

24 Jan 2011

NHLBI, HeartWare award $13.3M to study benefits of heart devices for heart failure

The University of Michigan Cardiovascular Center and the University of Pittsburgh have been awarded $13.3 million to explore the potential benefits of heart devices for the large and growing group of Americans with heart failure.

24 Jan 2011

Therapy News and Research

UH researchers to discuss computational surgery at MITIE

ASCO urges physicians, medical schools to improve quality of life for people with cancer

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

UB's therapeutic program helps teens with ADHD to become better drivers

Octapharma supports development of 'Diagnosis and Management of von Willebrand Disease' CE supplement

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Male celebrities admit to undergoing hair restoration surgery

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

World's largest sterile compounding center for oncology patients

Diamyd Medical to report European Phase III trial results for type 1 diabetes

Patients with chronic depression can benefit from pioneering neurosurgical treatment

Breast and lung cancer: Shared risk and treatment

Blocking rogue gene may stop cancer spread: Study

ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011

St. Jude Medical's Athena programmer DBS system receives Australian TGA approval

FDA accepts Optimer's fidaxomicin NDA for filing

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

NHLBI, HeartWare award $13.3M to study benefits of heart devices for heart failure

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News